Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...
Seeking Alpha on MSN2h
BioNTech to buy bispecific antibody developer Biotheus for up to $950MBioNTech (BNTX) plans to initiate multiple registration trials in 2024 and 2025 that will evaluate BNT327/PM8002 in combination with chemotherapy for the treatment of small cell lung cancer, non-small ...
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase ...
DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical ...
Hosted on MSN3h
I was diagnosed with an aggressive cancer at 36. Ten years later, I'm still learning to be confident in my body.I went through the process of applying for healthcare under the Affordable Health Care Act, but it took six months for me to ...
Brittany Pieniazek knew she had a chance of developing breast cancer. The Dyer resident’s mother and aunt had both been ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...
Cantargia AB (publ) hereby provides notification that the Nomination Committee (NC) has been appointed ahead of the 2025 Annual General Meeting (AGM), and consists of Arne Lööw (Fjärde ...
the completed OPALESCENCE 6 and PERTINENCE 7 investigator-initiated trials have demonstrated CAIX-targeting and dosimetry proof-of-concept for alpha therapy in triple-negative breast cancer, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback